Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease☆

Sabuncu, Tevfik; Vural, Hüseyín; Harma, Müge; Harma, Mehmet

doi:10.1016/s0009-9120(01)00245-4

Cited by 280 publications

(231 citation statements)

References 66 publications

Supporting

Mentioning

194

Contrasting

Unclassified

Order By: Relevance

“…20 This could explain the presence of oxidative stress even in the absence of obesity in our PCOS women. Our findings are in accordance with study done by Sabuncu T et al and Fenkci V et al 21,22 …”

supporting

confidence: 94%

Oxidative stress versus inflammation, a better predictor of cardiovascular disease risk in polycystic ovary syndrome

et al. 2016

View full text Add to dashboard Cite

supporting

confidence: 94%

Oxidative stress versus inflammation, a better predictor of cardiovascular disease risk in polycystic ovary syndrome

et al. 2016

View full text Add to dashboard Cite

“…Serum markers include C-reactive protein (4-6), adiponectin (7,8), plasminogen activator-1 (9), Von Willebrand factor (10), endothelin-1 (11), homocysteine (12) and markers of oxidative stress (13) and the majority of the studies have demonstrated that such abnormalities were related to insulin resistance and obesity in women with PCOS (14). Further, dyslipidemia is very common and may represent the most common metabolic abnormality in PCOS, with a prevalence of up to 70% according to the National Cholesterol Education Program criteria (14,15).…”

Section: Markers Of Cardiovascular Risk In Pcosmentioning

confidence: 99%

Long-term consequences of polycystic ovary syndrome on cardiovascular risk

Rizzo

Berneis²,

Spinas³

et al. 2009

Fertility and Sterility

View full text Add to dashboard Cite

2 CAPSULEPostmenopausal women with PCOS have increased cerebro-vascular events and cardiovascular morbidity. Our best long-term strategy is information, acknowledging women with PCOS of their risk for metabolic and cardiovascular diseases. 3 ABSTRACTMost available data suggest that the prevalence of cardiovascular diseases in women with polycystic ovary syndrome (PCOS) is smaller than what expected on the basis of the risk calculation during fertile age; therefore, we need many more studies on their long term cardiovascular consequences although evidence is accumulating that women with PCOS at postmenopausal age have an increase in cerebro-vascular events and in cardiovascular morbidity. These events are partially related to the persisting hyperandrogenism but are mostly correlated to the excessive body weight (mainly to the visceral obesity); this suggests that our best long term strategy is the information, acknowledging women with PCOS of their high risk for metabolic and cardiovascular diseases.

show abstract

“…PCOS is also associated with increased oxidative stress and systemic inflammation [96][97][98] . Furthermore, antioxidant reserve appears to be compromised in women with PCOS 97 .…”

Section: Pathophysiology Of Pcosmentioning

confidence: 99%

“…PCOS is also associated with increased oxidative stress and systemic inflammation [96][97][98] . Furthermore, antioxidant reserve appears to be compromised in women with PCOS 97 . Even lean women with PCOS exhibit increased oxidative stress, as measured by levels of malonyldialdehyde, a marker of lipid peroxidation, and they have decreased serum total antioxidant levels compared to controls 56 .…”

Section: Pathophysiology Of Pcosmentioning

confidence: 99%

“…Even lean women with PCOS exhibit increased oxidative stress, as measured by levels of malonyldialdehyde, a marker of lipid peroxidation, and they have decreased serum total antioxidant levels compared to controls 56 . Recent evidence suggests that inflammatory cytokines and measures of oxidative stress, such as tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP) 99,100 , may play a role in the dysregulation of the theca-interstitial compartment, and both of these factors are elevated in PCOS 97,98,101,102 .…”

Section: Pathophysiology Of Pcosmentioning

confidence: 99%

See 1 more Smart Citation

Statins in the Treatment of Polycystic Ovary Syndrome

Kodaman

Dulęba²

2008

Semin Reprod Med

View full text Add to dashboard Cite

Many women of reproductive age are affected by polycystic ovary syndrome (PCOS), a heterogeneous endocrinopathy characterized by androgen excess, chronic oligo-anovulation and/or polycystic ovarian morphology. In addition, PCOS is often associated with insulin resistance, systemic inflammation and oxidative stress which, on one hand, lead to endothelial dysfunction and dyslipidemia with subsequent cardiovascular sequelae and, on the other hand, to hyperplasia of the ovarian theca compartment with resultant hyperandrogenism and anovulation. While traditionally statins have been used to treat dyslipidemia by blocking HMG-CoA reductase, the rate limiting step in cholesterol biosynthesis; in fact, they possess pleiotropic actions, resulting in antioxidant, antiinflammatory and anti-proliferative effects. Statins offer a novel therapeutic approach to PCOS in that they address the dyslipidemia associated with the syndrome, as well as hyperandrogenism/ hyperandrogenemia. These actions may be due to an inhibition of the effects of systemic inflammation and insulin resistance/hyperinsulinemia. Evidence to date, both in vitro and in vivo, suggests that statins have potential in the treatment of PCOS; however, further clinical trials are needed before they can be considered a standard of care in the medical management of this common endocrinopathy.

show abstract

Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease☆

Cited by 280 publications

References 66 publications

Oxidative stress versus inflammation, a better predictor of cardiovascular disease risk in polycystic ovary syndrome

Oxidative stress versus inflammation, a better predictor of cardiovascular disease risk in polycystic ovary syndrome

Long-term consequences of polycystic ovary syndrome on cardiovascular risk

Statins in the Treatment of Polycystic Ovary Syndrome

Contact Info

Product

Resources

About